pdufa.bio
Home › CRL letters › March 2026

FDA complete response letters, March 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 10, 2026 12:55 AM ET

The FDA's public release of complete response letters holds 2 letters dated March 2026 (openFDA, last updated 2026-08-26). Of the 23 FDA decisions on PDUFA goal dates pdufa.bio tracked in March 2026, 2 were Complete Response Letters.

Released by the FDA, dated March 2026 · 2

Letter dateCompanyApplicationopenFDA statusLetter
2026-03-16Aldeyra Therapeutics, Inc.NDA 216442Unapprovedletter (PDF)
2026-03-05Rosemont Pharmaceuticals Holdings, Inc.NDA 220140Unapprovedletter (PDF)

Complete Response Letters among decisions pdufa.bio tracked · 2

FDA actionTickerDrugSource
2026-03-17ALDXReproxalap (ADX-102) - (CHAMBdecision page
2026-03-05OTLKLYTENAVA (bevacizumab-vikg) /decision page
A Complete Response Letter is the FDA's notice that it will not approve an application in its current form; it is not a permanent rejection, and the sponsor can resubmit. The two counts come from different records and are not added together. ← February 2026 · April 2026 → · all released letters · every CRL decision we tracked